蛋白质组学在阿尔采末病中的研究进展

蛋白质组学是基因组时代产生的一门重要学科,是从整体水平对蛋白质的综合分析。阿尔采末病（Alzheimer’s disease,AD）是常见而复杂的神经退行性疾病之一。应用蛋白质组学对AD进行研究,不仅可在蛋白质水平上揭示疾病的本质,还有助于全面探讨AD的病理机制,建立诊断标准,发现药物治疗靶点。本文从病理机制（特别是蛋白质翻译后修饰）、发现临床生物标签及治疗药物三个方面,对蛋白质组学在AD中的研究进展进行了综替。     

药物成瘾的蛋白质组学研究

药物成瘾涉及脑内多种蛋白含量、结构及功能的复杂改变,主要涉及代谢酶类、细胞骨架蛋白、分子伴侣、细胞内信号途径相关蛋白、突触功能相关蛋白和氧化还原相关蛋白等类型。蛋白质组学能对生理与病理状态下的体液、组织或细胞中基因组编码的所有蛋白质组分进行高通量的综合分析,针对筛选出的有意义“候选”蛋白（candidate protein）进行深入验证研究,不仅可能从蛋白质水平上阐明成瘾的神经生物学作用机制,还有助于建立诊断标准,发现抗成瘾药物治疗的潜在靶点。     

癌症差异蛋白质组学研究中样品分离和鉴定分析技术

随着人类基因组测序的完成,癌症研究的重点从基因组学转移到蛋白质组学研究中。癌症研究中的差异蛋白质组学技术也飞速发展,包括癌症样品制备、分离,蛋白质鉴定分析、蛋白质组定量研究和翻译后修饰研究等。这些技术极大地推动了与癌症相关的差异蛋白质组学研究,使蛋白质组学在癌症早期诊断、治疗,监测以及发现新药物治疗靶标方面发挥更大的作用。本文主要综述了近年来癌症差异蛋白质组学研究中样品分离和鉴定分析技术。     

基于质谱的药物蛋白质组学研究

药物蛋白质组学是蛋白质组学技术在药物发现和药物开发过程中的应用。基于质谱的药物蛋白质组学是蛋白质组学的一个分支,在药物研发过程中起了越来越重要的作用。本文就近年来基于质谱的药物蛋白质组学在药物作用机制、药物潜在靶点的筛选及疾病的耐药性机制等研究中取得的进展进行综述。     

基于SVM 的药物靶点预测方法及其应用

目的:基于已知药物靶点和潜在药物靶点蛋白的一级结构相似性,结合SVM技术研究新的有效的药物靶点预测方法。方法:构造训练样本集,提取蛋白质序列的一级结构特征,进行数据预处理,选择最优核函数,优化参数并进行特征选择,训练最优预测模型,检验模型的预测效果。以G蛋白偶联受体家族的蛋白质为预测集,应用建立的最优分类模型对其进行潜在药物靶点挖掘。结果:基于SVM所建立的最优分类模型预测的平均准确率为81.03%。应用最优分类器对构造的G蛋白预测集进行预测,结果发现预测排位在前20的蛋白质中有多个与疾病相关。特别的,其中有两个G蛋白在治疗靶点数据库(TTD)中显示已作为临床试验的药物靶点。结论:基于SVM和蛋白质序列特征的药物靶点预测方法是有效的,应用该方法预测出的潜在药物靶点能够为发现新的药靶提供参考。     

化学基因组学在抗真菌药物研究中的应用CSCD

真菌感染特别是侵袭性感染严重威胁人类健康,而我们应对真菌感染的药物种类却很少。基于细胞表型变化的抗真菌药物筛选,容易获得活性先导物,但后续对其作用靶点和作用机制的研究通常需要耗费更多的时间和精力,这已成为抗真菌药物研发的瓶颈。识别活性化合物的分子靶点,对于进一步优化改造先导物获得高效低毒的候选药物至关重要。化学基因组学能在活细胞基因组水平上发现先导物的作用靶点,利用该策略,近年来已有多个抗真菌先导物发现了作用靶点。该文主要介绍了化学基因组学的技术特点,以及近年来在发现抗真菌先导物作用靶点方面的应用。     

药物靶标蛋白筛选的化学蛋白质组学研究进展

药物或生物活性物质通过与靶蛋白结合而发挥功能,研究表明,大多数药物具有多个作用靶点,药物靶标的发现有助于药物前体的筛选和作用机制的研究,同时对其耐药性等副作用的解决方案提供理论指导.基于生物质谱技术的蛋白质组学可对蛋白质进行高通量的定性定量分析,为药物靶标的筛选提供了全新的平台.本文综述了基于固载药物和游离药物模式的药物靶标蛋白筛选相关方法和应用研究的最新进展,为基于生物质谱技术的化学蛋白质组学研究提供参考.     

热蛋白质组学分析：一种全面评估蛋白质状态的技术

热蛋白质组学分析（thermal proteome profiling,TPP）是细胞热漂移测定（cellular thermal shift assay,CETSA）与定量质谱（quantitative mass spectrometry,MS）的结合,所以也称为MS-CETSA。热蛋白质组学分析通过测量不同加热温度下细胞或细胞裂解物中可溶蛋白的含量来确定整个蛋白质组的稳定性。蛋白质可以在与药物或代谢物等小分子、核酸或其他蛋白质相互作用或在翻译后修饰时改变其热稳定性,而热蛋白质组学分析可以根据有无配体结合蛋白质的热稳定性差异来确定靶蛋白。目前热蛋白质组学分析已成功应用于识别药物的靶点和脱靶点,探究蛋白质-代谢物和蛋白质-蛋白质的相互作用。总体上,国内对这个技术的了解仍然欠缺,对此,文中对热蛋白质组学分析的原理、方法、应用以及优势与局限性进行了综述。     

基于网络特征的药物靶蛋白识别

蛋白质很少孤立得发挥作用,往往通过网络中彼此互作来共同行使功能.因此分析药物靶蛋白在生物学网络中的性质将十分有助于从信息学角度理解药物的作用机制.但目前尚无研究对药物靶蛋白在人类蛋白质互作网络中的拓扑特性给与具体的分析和描述.本文首先将药物靶蛋白映射到人类蛋白质互作网络中,进而分析了药物作用靶蛋白在互作网络中的5种拓扑指标,并与互作网络中全蛋白质组集合及非药物靶点集合的拓扑指标进行了对比.结果显示,药物靶蛋白之间具有更高的连通性,信息能够得到更快得传递.基于这些拓扑特征,将互作网络中的所有蛋白进行排序.发现排序在前100位的蛋白中有48个是Drugbank中记录的药物靶点,另外的52个蛋白中有9个蛋白已在TTD,Matador等数据库中被记录为药物靶点,还有部分蛋白通过文献检索被证实为药物靶点.     

蛋白质组学在神经退行性疾病中的研究进展

蛋白质组学是后基因组时代兴起的新型学科,是从整体水平对蛋白质的综合分析。阿尔茨海默病、帕金森病、肌萎缩侧索硬化症等是最常见的神经退行性疾病。应用蛋白质组学对它们进行研究,不仅可从蛋白质水平上揭示疾病的本质,还有助于全面探讨其病理机制,建立诊断标准,发现药物治疗靶点。     

Biomarker discovery: proteome fractionation and separation in biological samples.

Proteomics, analogous with genomics, is the analysis of the protein complement present in a cell, organ, or organism at any given time. While the genome provides information about the theoretical status of the cellular proteins, the proteome describes the actual content, which ultimately determines the phenotype. The broad application of proteomic technologies in basic science and clinical medicine has the potential to accelerate our understanding of the molecular mechanisms underlying disease and may facilitate the discovery of new drug targets and diagnostic disease markers. Proteomics is a rapidly developing and changing scientific discipline, and the last 5 yr have seen major advances in the underlying techniques as well as expansion into new applications. Core technologies for the separation of proteins and/or peptides are one- and two-dimensional gel electrophoresis and one- and two-dimensional liquid chromatography, and these are coupled almost exclusively with mass spectrometry. Proteomic studies have shown that the most effective analysis of even simple biological samples requires subfractionation and/or enrichment before protein identification by mass spectrometry. Selection of the appropriate technology or combination of technologies to match the biological questions is essential for maximum coverage of the selected subproteome and to ensure both the full interpretation and the downstream utility of the data. In this review, we describe the current technologies for proteome fractionation and separation of biological samples, based on our lab workflow for biomarker discovery and validation.     

Proteomics and biomarkers in clinical trials for drug development

Proteomics allows characterization of protein structure and function, protein-protein interactions, and peptide modifications. It has given us insight into the perturbations of signaling pathways within tumor cells and has improved the discovery of new therapeutic targets and possible indicators of response to and duration of therapy. The discovery, verification, and validation of novel biomarkers are critical in streamlining clinical development of targeted compounds, and directing rational treatments for patients whose tumors are dependent upon select signaling pathways. Studies are now underway in many diseases to examine the immune or inflammatory proteome, vascular proteome, cancer or disease proteome, and other subsets of the specific pathology microenvironment. Successful assay verification and biological validation of such biomarkers will speed development of potential agents to targetable dominant pathways and lead to selection of individuals most likely to benefit. Reconsideration of analytical and clinical trials methods for acquisition, examination, and translation of proteomics data must occur before we march further into future of drug development.     

蛋白质组学技术及其在生物医学上的应用

蛋白质组学部分承用了创立于二十多年前的二维电泳技术。基于其高分辩能力 ,二维电泳主要用于分离和检测复杂混合物中的蛋白质。虽然没有获得更多的改进 ,但是二维电泳结合了通过质谱测定蛋白质的最新进展而成为蛋白质组学中的一项重要技术。随着人类基因组计划项目的完成及由此而产生的大量基因数据库和使用这些数据的生物信息技术 ,科学家们的下一个目标是解析生物体的完整蛋白质组 ,把蛋白质组学数据与基因组学数据关联起来并有机地结合而成为一项有力的工具以阐明病理学中的蛋白质功能、衰老的过程及发现新药目标蛋白质和疾病标识物等。文章综述了蛋白质组学技术的最新知识及其在生物医学研究中的潜在应用     

Recent Progress in Functional Genomic Research in Plasmodium falciparum

With the completion and near completion of many malaria parasite genome-sequencing projects, efforts are now being directed to a better understanding of gene functions and to the discovery of vaccine and drug targets. Inter- and intraspecies comparisons of the parasite genomes will provide invaluable insights into parasite evolution, virulence, drug resistance, and immune invasion. Genome-wide searches for loci under various selection pressures may lead to discovery of genes conferring drug resistance or encoding for protective antigens. In addition, the Plasmodium falciparum genome sequence provides the basis for the development of various microarrays to monitor gene expression and to detect nucleotide substitution and deletion/amplification. Genome-wide profiling of the parasite proteome, chromatin modification, and nucleosome position also depend on availability of the parasite genome. In this brief review, we will highlight some recent advances and studies in characterizing gene function and related phenotype in P. falciparum that were made possible by the genome sequence, particularly the development of a genome-wide diversity map and various high-throughput genotyping methods for genome-wide association studies (GWAS).     

Proteomics in biomarker discovery and drug development

Proteomics is a research field aiming to characterize molecular and cellular dynamics in protein expression and function on a global level. The introduction of proteomics has been greatly broadening our view and accelerating our path in various medical researches. The most significant advantage of proteomics is its ability to examine a whole proteome or sub-proteome in a single experiment so that the protein alterations corresponding to a pathological or biochemical condition at a given time can be considered in an integrated way. Proteomic technology has been extensively used to tackle a wide variety of medical subjects including biomarker discovery and drug development. By complement with other new technique advances in genomics and bioinformatics, proteomics has a great potential to make considerable contribution to biomarker identification and to revolutionize drug development process. This article provides a brief overview of the proteomic technologies and their application in biomarker discovery and drug development.     

Genomics: success or failure to deliver drug targets?

For decades, the entire pharmaceutical industry has focused on a limited number of drug targets. Owing to advances in molecular biology and genome technology at the beginning of the 1990s, discovery and isolation of a large number of genes from the human genome became feasible. This triggered a multi billion US dollars investment by both biotechnology and pharmaceutical companies to gain access to and patent as many potential drug targets as possible. Although the combined effort of publicly funded projects and private investments resulted in rapid identification of essentially all genes of the human genome, harnessing this information to enable drug discovery has turned out to be more challenging and time consuming than initially anticipated.     

Pharmaco-proteomic analysis: application of proteomic analysis to the discovery and development of new drugs

Pharmacoproteomics may be defined as proteomics applied to the discovery of new therapeutic targets and to the study of drug effects. Proteomics is a powerful technique for analyzing the protein expression profiles in a biological system and its modifications in response to a stimulus or according to the physiological or pathophysiological states. Thus it is a technique of choice for the discovery of new drug targets. It is also an interesting approach for the study of the mode of action of treatments and preclinical drug development. This pharmacoproteomic approach may be particularly useful for the research of new molecular alterations implicated in type 2 diabetes and/or obesity and for the further characterization of existing or new drugs.     

The progress made in determining the Mycobacterium tuberculosis structural proteome

Mycobacterium tuberculosis is a highly infectious pathogen that is still responsible for millions of deaths annually. Effectively treating this disease typically requires a course of antibiotics, most of which were developed decades ago. These drugs are, however, not effective against persistent tubercle bacilli and the emergence of drug-resistant stains threatens to make many of them obsolete. The identification of new drug targets, allowing the development of new potential drugs, is therefore imperative. Both proteomics and structural biology have important roles to play in this process, the former as a means of identifying promising drug targets and the latter allowing understanding of protein function and protein-drug interactions at atomic resolution. The determination of M. tuberculosis protein structures has been a goal of the scientific community for the last decade, who have aimed to supply a large amount of structural data that can be used in structure-based approaches for drug discovery and design. Only since the genome sequence of M. tuberculosis has been available has the determination of large numbers of tuberculosis protein structures been possible. Currently, the molecular structures of 8.5% of all the pathogen's protein-encoding ORFs have been determined. In this review, we look at the progress made in determining the M. tuberculosis structural proteome and the impact this has had on the development of potential new drugs, as well as the discovery of the function of crucial mycobaterial proteins.     

Proteomics in the post-genome age.

The genome sequencing effort has helped spawn the burgeoning field of proteomics. This review article examines state-of-the-art proteomics methods that are helping change the discovery paradigm in a variety of biological disciplines and, in particular, protein biochemistry. The review discusses both classical and novel methods to perform high-throughput qualitative and quantitative "global" as well as targeted proteome analysis of complex biological systems. From a drug discovery standpoint, the synergy between genomics and proteomics will help elucidate disease mechanisms, identify novel drug targets, and identify surrogate biomarkers that could be used to conduct clinical trials.